Recently, IL-1β blocking therapy was demonstrated to decrease the risk for stroke in coronary artery disease patients with inflammatory atherosclerosis [82], while its modulatory role in cancer [83], macular degeneration [91] and neurodegenerative disorders [1, 38, 40–42, 95] is also intensively investigated [93]. The gene discussed is IL1B; the disease is cancer.